P3 Health Partners Inc. (PIII) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted liquidity concerns, reliance on external factors for growth, and a broad-based guidance reduction due to underperformance. Despite some operational improvements, the Q&A revealed management's vague responses to critical questions, raising uncertainties. The company's cash position and dependency on future joint ventures further add to the negative sentiment. The negative aspects outweigh the positive, suggesting a negative stock price reaction in the short term.
Key Financial Performance
Capitated Revenue $341.6 million for the quarter, approximately $982 per member per month. This represents a 6.4% increase year-over-year, attributed to improved burden of illness documentation and better contract terms.
Medical Margin $4.4 million for the quarter, or $13 per member per month, compared to $500,000 or $1 per member per month in the prior period. This improvement is due to stable medical cost trends and adjustments for prior year items.
Operating Expense $21.1 million for the quarter, a 33% reduction from $31.6 million in the prior year period. This decrease is due to targeted reductions in administrative headcount and support costs, while reinvesting in roles that influence clinical performance.
Adjusted EBITDA Loss of $45.9 million for the quarter and $85.2 million year-to-date. On a normalized basis, the year-to-date loss is approximately $70.1 million, reflecting stable medical cost trends and improved clinical and utilization management programs.
Cash Balance $37.7 million at the end of the quarter, maintained through disciplined working capital management and resource allocation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Care Enablement Model: The model embeds clinical support and data-driven workflows directly into provider practices, improving documentation accuracy, quality performance, and care coordination.
Strategic joint venture: This will add approximately 13,000 fully accretive ACO members, improving profitability and cash flow, with an additional 25,000 Medicare Advantage lives in the pipeline for 2026.
Capitated revenue growth: Capitated revenue increased by roughly 6%, with normalized medical cost trends remaining flat year-over-year despite rising industry costs.
Operational improvement plan: Achieved over $100 million in EBITDA improvement year-over-year.
Provider network rationalization: Exiting groups that do not align clinically or economically and focusing on Tier 1 providers who deliver better outcomes.
EBITDA expansion opportunities: Identified $120 million to $170 million in EBITDA opportunities over the next 5 quarters, driven by improved alignment with population burden of illness, scaling clinical programs, and contractual improvements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Performance: The company reported an adjusted EBITDA loss of $45.9 million for the quarter and $85.2 million year-to-date. Even after normalization adjustments, the year-to-date adjusted EBITDA loss was $70 million, indicating ongoing financial challenges.
Revenue Recognition: Unfavorable midyear settlement adjustments impacted capitated revenue, highlighting issues with visibility and predictability in revenue recognition processes.
Cost Management: While operating expenses improved by $10.4 million year-over-year, the company still faces challenges in aligning its cost structure with its operating model and scaling the business effectively.
Provider Network Rationalization: The company is exiting provider groups that do not align clinically or economically, which could disrupt operations and relationships in the short term.
Membership Growth: Although membership was in line with expectations, the company is relying heavily on future growth from strategic joint ventures and pipeline opportunities, which may not materialize as planned.
Cash Flow and Liquidity: The company ended the quarter with $37.7 million in cash, raising concerns about liquidity and the ability to sustain operations without additional funding.
Regulatory and Competitive Environment: The company expects to benefit from improved rate environments and sustainable benefit designs, but these are external factors that could change, introducing uncertainty.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Membership Growth: The company is adding approximately 13,000 fully accretive ACO members through a strategic joint venture, with an additional 25,000 Medicare Advantage lives in the pipeline for 2026.
Profitability Outlook: The company is positioned for meaningful profitability in 2026, supported by operational improvements and strategic initiatives.
EBITDA Expansion: The company is executing against $120 million to $170 million in EBITDA expansion opportunities for 2026, driven by improved alignment with population burden of illness, scaling clinical and operational programs, contractual improvements, and stabilization of the product and benefit environment.
Provider Network Optimization: The company is rationalizing its provider network to improve margin performance by exiting groups that do not align clinically or economically and growing where the Care Enablement Model delivers strong outcomes.
Clinical and Operational Programs: The company plans to expand Tier 1 provider participation, standardize clinical workflows across markets, and further integrate data and clinical insights into provider practices.
Macroeconomic Tailwinds: The company expects favorable macroeconomic conditions in 2026, including improved rate environments and more sustainable benefit designs from payors.
Adjusted EBITDA Guidance for 2025: The company revised its full-year adjusted EBITDA guidance to a range of minus $110 million to minus $95 million, reflecting current expectations and improved controls.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What convinces the plans to see margin in their MA books, especially when they're trying to increase their margins for 2026?
A:Aric Coffman explained that there are differences across geographies in benefit design, but the changes meet expectations. The motivation for payors includes investments in high-risk patients, net expense reduction, and Stars and quality improvements.
Q:Have you made an attempt to have the plans have more skin in the game or participate in a potential surplus? Are all contracts for 2026 full capitation?
A:Aric Coffman stated that they take the risk from payors, who get their administrative margin, and they use a percent of premium to run their business. The partnership involves bilateral accountability for outcomes, and they have increased meeting cadence and set new expectations.
Q:Was the guidance reduction driven by a single payor or market, or is it more broad-based?
A:Leif Pedersen clarified that the guidance reduction was broad-based, primarily due to midyear settlements being less than expected and delays in medical cost initiatives. Structural controls have been implemented to address these issues.
Q:How are noncore assets performing, and is there an opportunity to shed them in 2026 or 2027?
A:Leif Pedersen mentioned headwinds in one market and stated that part of the 2026 EBITDA expansion includes contractual adjustments related to that market.
Q:What was the prior period dollar amount in the third quarter, and how much was the settlement impact?
A:Leif Pedersen reported a $3 million prior period decrement and a $21 million midyear true-up impact, totaling a $24 million unfavorable impact in Q3.
Q:What are the odds of another prior period adjustment in 2026 related to 2025 claims, and why weren't those claims expenses booked in 2024?
A:Leif Pedersen explained that nondelegated plans and delayed data caused the issue. Improved processes and expectations with payors should prevent such adjustments in the future.
Q:What are the PMPM revenue growth expectations in 2026 based on improved coding and rate increases?
A:Aric Coffman stated that the aggregate base rate improvement is 5%, and coding improvements are progressing year-over-year. Full guidance will be available next quarter.
Q:What was the PMPM cost trend in the quarter, and what does it imply for 2026?
A:Aric Coffman noted that Part A and Part B costs are flat year-to-date 2025 versus full-year 2024. This trend could lead to at least 500 basis points of gross margin expansion in 2026.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing how they would ensure payors pay more attention to medical management and align incentives, using vague language about bilateral accountability and increased meeting cadence without providing specific actions or data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Care Enablement
Enablement Model
Gabby
Tier provider
accuracy quality
adjustment
alignment population
approach
basis item
cadence
care coordination
coordination utilization
core
cost structure
cost trend
date loss
discipline
documentation accuracy
driver
effort
element
expansion
foundation
item date
loss date
market provider
population burden
process visibility
profitability
progress cost
provider alignment
provider practice
reflection
resource
settlement
share life
specialty
stability
stabilization
visibility predictability
workflow
PIII Transcript
P3 Health Partners Inc. (PIII) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance with a 25% increase in adjusted EBITDA and a 10% increase in medical margin. Despite a slight decline in cash flow, the overall financial health appears robust. The new partnership contributing to revenue growth and a positive outlook for 2026 further support a positive sentiment. The lack of discussion on strategic initiatives and operational updates does not overshadow the strong financial metrics and optimistic guidance, suggesting a likely stock price increase in the short term.
P3 Health Partners Inc. (PIII) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call summary presents a mixed picture: some financial improvements, but ongoing challenges. The company shows a slight improvement in EBITDA and revenue, but liquidity risks and declining medical margins are concerning. The Q&A reveals that new agreements like the Nebraska deal could bring future growth, but execution risks remain. Overall, the positive aspects are balanced by significant uncertainties, leading to a neutral sentiment.
P3 Health Partners Inc. (PIII) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call highlighted liquidity concerns, reliance on external factors for growth, and a broad-based guidance reduction due to underperformance. Despite some operational improvements, the Q&A revealed management's vague responses to critical questions, raising uncertainties. The company's cash position and dependency on future joint ventures further add to the negative sentiment. The negative aspects outweigh the positive, suggesting a negative stock price reaction in the short term.
P3 Health Partners Inc. (PIII) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed picture: strong operational improvements and a positive outlook for 2025, including breakeven achievements and renegotiation progress, are offset by current losses and adjustments impacting financials negatively. The Q&A reveals management's confidence in overcoming past issues but also highlights uncertainties in guidance and market performance. The lack of clear responses to some analyst questions further tempers optimism. Given these factors, the stock price is likely to remain stable in the short term, with potential for improvement as execution on strategies progresses.
PIII Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
